GlassScriptPhysician profile
Jacob M Burch
NPI 1053806570
$3,215.40
in general payments reported to CMS, 2019-2025
27 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.51 · 2020: $42.81 · 2021: $22.14 · 2022: $533 · 2023: $766 · 2024: $553 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,141.85 | 2022-2025 | Rinvoq, Creon, Skyrizi |
| Intercept Pharmaceuticals, INC. | $321.36 | 2022-2024 | Ocaliva |
| Janssen Biotech, INC. | $302.65 | 2023-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.37 | 2022-2025 | Xifaxan, Relistor, Trulance |
| E.R. Squibb & Sons, L.L.C. | $186.94 | 2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $119.19 | 2024-2025 | Dupixent |
| Madrigal Pharmaceuticals | $116.43 | 2024-2025 | Rezdiffra |
| Genzyme Corporation | $104.94 | 2025 | |
| Janssen Scientific Affairs, LLC | $88.74 | 2022 | |
| Gilead Sciences, INC. | $74.06 | 2024 | Epclusa |
| Lumendi LLC | $68.04 | 2025 | |
| Pfizer INC. | $51.81 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.90 | 2024 | Entyvio |
| Phathom Pharmaceuticals, INC. | $45.70 | 2025 | Voquezna |
| Olympus America INC. | $24.71 | 2025 | Endoclot Phs, Single Use Electrosurgical Hemostatic Forceps |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $23.47 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.79 | 2020 | |
| United Therapeutics Corporation | $22.14 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $20.84 | 2024 | Iqirvo |
| Novartis Pharmaceuticals Corporation | $20.02 | 2020 | |
| Alexion Pharmaceuticals, INC. | $19.68 | 2019 | |
| Celgene Corporation | $18.25 | 2023 | Zeposia |
| Celltrion USA INC. | $17.08 | 2025 | Vegzelma |
| Ardelyx, INC. | $16.19 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.89 | 2023 | Cyltezo |
| Amgen INC. | $13.73 | 2019 | |
| Sanofi Pasteur INC. | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Burch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.